Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

Novartis AG L (0QLR)

London
Currency in CHF
90.37
-0.34(-0.37%)
Closed
0QLR Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
89.8190.48
52 wk Range
83.61233.50
Key Statistics
Edit
Bid/Ask
88.11 / 92.62
Prev. Close
90.7
Open
90.45
Day's Range
89.81-90.48
52 wk Range
83.61-233.5
Volume
546.39K
Average Volume (3m)
539.28K
1-Year Change
7.51%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
0QLR Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
115.73
Upside
+28.86%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 28 consecutive years
Show more

Novartis AG Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Employees
76057

Compare 0QLR to Peers and Sector

Metrics to compare
0QLR
Peers
Sector
Relationship
P/E Ratio
17.4x17.5x−0.6x
PEG Ratio
0.13−0.360.00
Price/Book
4.7x1.8x2.6x
Price / LTM Sales
4.1x2.3x3.2x
Upside (Analyst Target)
-18.3%44.6%
Fair Value Upside
Unlock23.1%7.3%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.65
Dividend Yield
3.64%
Industry Median 2.52%
Annualised payout
3.3000
Paid annually
5-Years Growth
-
Growth Streak

People Also Watch

39.210
CRDI
-0.63%
28.84
UBSG
-0.41%
785.5
NOVOb
+1.88%
651.800
RHMG
-0.97%

FAQ

What Is the Novartis (0QLR) Stock Price Today?

The Novartis stock price today is 90.37

What Stock Exchange Does Novartis Trade On?

Novartis is listed and trades on the London stock exchange.

What Is the Stock Symbol for Novartis?

The stock symbol for Novartis is "0QLR."

Does Novartis Pay Dividends? What’s The Current Dividend Yield?

The Novartis AG dividend yield is 3.66%.

What Is the Novartis Market Cap?

As of today, Novartis market cap is 179.55B.

What is Novartis Earnings Per Share?

The Novartis EPS is 8.65.

From a Technical Analysis Perspective, Is 0QLR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.